Brought to you by 
Celgene licenses Thalomid to Pharmion
16 Nov 2021
Executive Summary
Celgene (small-molecule drugs for cancer and immunological diseases) has licensed Thalomid (thalidomide) to Pharmion (focuses on hematology and oncology therapeutics) to treat cancer and inflammatory diseases in foreign markets excluding Canada, China, Japan, Taiwan, and Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene licenses Thalomid to Pharmion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice